Clinical and biological database for people with advanced ovarian, peritoneal, or fallopian tube cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational database run at the Centre Oscar Lambret that will enroll patients at the time of initial care and confirm inclusion when FIGO stage IIB–IV is established. Participants give consent for an extra blood draw, leftover routine tumor and fluid samples, and repeated quality-of-life and anxiety questionnaires over a two-year active participation period. Clinical, biological, and patient-reported data are entered into a trial-specific database with the goal of building prognostic models of overall survival. The project plans to recruit 371 patients over five years and will continue to collect standard-care and survival data beyond the active participation window.

Why it matters

Who can join: the full rules

Eligibility criteria for pre-registration:

* Patient aged 18 or over
* Informed consent warranted
* Patient affiliated to a social security regimen
* Suspected diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages)
* Pre-registration during standard care at the Oscar Lambret Centre, from diagnosis and before confirmation of definitive FIGO stage

Non eligibility criteria for pre-registration:

* Patient deprived of liberty or under curatorship or guardianship
* Refusal to participate

Inclusion criteria:

• Confirmed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer (IIB to IV FIGO stages)

Exclusion criteria:

• Dismissed diagnosis of advanced and invasive ovarian cancer and/or primary peritoneal cancer and/or fallopian tube cancer , or other type of cancer

Where it's running

• Centre Oscar Lambret
  Lille, France Recruiting

Study contacts

• Study coordinator: Alicia Probst, PhD
• Email: promotion@o-lambret.fr
• Phone: 33320295918

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• Personalized timing of interval debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

  This study will see if using the CA125 drop rate (KELIM) to decide when to do interval debulking surgery helps people with advanced ovarian, fallopian tube, or peritoneal cancer who are receiving neoadjuvant chemotherapy.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT07022535

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• Fluzoparib with or without Bevacizumab for treating advanced ovarian cancer

  This study is testing whether a new drug called Fluzoparib, alone or with another drug called Bevacizumab, can help people with advanced ovarian cancer caused by BRCA1/2 mutations do better than standard chemotherapy.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06735326

• Using blood volume management during surgery for ovarian cancer patients

  This study tests if a blood management technique called acute normovolemic hemodilution can help women with advanced ovarian cancer during surgery by reducing the need for blood transfusions and improving safety.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06290193

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.